Does Cosentyx Help Skin Symptoms?
Cosentyx (secukinumab) treats plaque psoriasis, a skin condition causing red, scaly patches. It blocks interleukin-17A (IL-17A), a protein driving inflammation in psoriasis. Clinical trials show it clears skin in many patients: 80-90% achieve at least 75% improvement (PASI 75) after 12 weeks, with some reaching nearly clear skin (PASI 90).[1][2]
How Quickly Does Cosentyx Clear Psoriasis?
Patients often see skin improvements within 4 weeks. Full effects peak at 12-16 weeks. Long-term data from trials like FUTURE and CLEAR confirm sustained clearing up to 5 years, with over 80% maintaining PASI 75.[1][3]
What Skin Conditions Does Cosentyx Treat Besides Psoriasis?
FDA approves it for:
- Moderate-to-severe plaque psoriasis in adults and children 6+.
- Psoriatic arthritis (often with skin involvement).
- Hidradenitis suppurativa (painful skin nodules).[1]
It does not treat eczema, acne, or non-inflammatory skin issues.
Cosentyx vs. Other Psoriasis Treatments
| Treatment | Mechanism | Skin Clearance Rate (PASI 75 at 12 weeks) | Injection Frequency |
|-----------|-----------|------------------------------------------|---------------------|
| Cosentyx | IL-17 inhibitor | 80-84% | Monthly after loading |
| Humira (adalimumab) | TNF inhibitor | 71-79% | Every 2 weeks |
| Stelara (ustekinumab) | IL-12/23 inhibitor | 66-76% | Every 12 weeks |
| Skyrizi (risankizumab) | IL-23 inhibitor | 87-89% | Every 12 weeks[1][4] |
Cosentyx outperforms older TNF drugs on skin but trails some newer IL-23 options in head-to-head speed.
Common Skin-Related Side Effects
Injection-site reactions occur in 10-15% (redness, itching). Upper respiratory infections (not skin) are most frequent. Rare severe skin issues include new psoriasis plaques or allergic rashes. Monitor for candidiasis, which can affect skin/mouth.[1][2]
Who Can't Use Cosentyx for Skin Issues?
Avoid if active Crohn's disease, tuberculosis, or recent live vaccines. Not for pregnant/nursing patients without doctor discussion. Liver/kidney issues require monitoring.[1]
Sources:
[1] [Cosentyx.com (Novartis prescribing info)]
[2] [FDA Label (2023)]
[3] [NEJM Trial (2016)]
[4] [DrugPatentWatch.com]